AU2002214854A1 - Lipid formulations for target delivery - Google Patents

Lipid formulations for target delivery

Info

Publication number
AU2002214854A1
AU2002214854A1 AU2002214854A AU1485402A AU2002214854A1 AU 2002214854 A1 AU2002214854 A1 AU 2002214854A1 AU 2002214854 A AU2002214854 A AU 2002214854A AU 1485402 A AU1485402 A AU 1485402A AU 2002214854 A1 AU2002214854 A1 AU 2002214854A1
Authority
AU
Australia
Prior art keywords
target delivery
lipid formulations
lipid
active agent
systemic delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214854A
Inventor
Pieter R. Cullis
David B. Fenske
Ian Maclachlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Inex Pharmaceuticals Corp
Original Assignee
University of British Columbia
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Inex Pharmaceuticals Corp filed Critical University of British Columbia
Publication of AU2002214854A1 publication Critical patent/AU2002214854A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides lipid-based systemic delivery vehicles and method for selectively targeting an active agent to a specific tissue site. The methods include designing a lipid-based systemic delivery vehicle having a plurality of constitutent parts, and thereafter varying the amounts of each of the plurality of constituent parts to impart tissue selectivity. After tissue selectivity is imparted it is possible to selectively target an active agent to a specific tissue site.
AU2002214854A 2000-10-25 2001-10-25 Lipid formulations for target delivery Abandoned AU2002214854A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24318500P 2000-10-25 2000-10-25
US60/243,185 2000-10-25
PCT/CA2001/001513 WO2002034236A2 (en) 2000-10-25 2001-10-25 Lipid formulations for target delivery

Publications (1)

Publication Number Publication Date
AU2002214854A1 true AU2002214854A1 (en) 2002-05-06

Family

ID=22917671

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214854A Abandoned AU2002214854A1 (en) 2000-10-25 2001-10-25 Lipid formulations for target delivery

Country Status (7)

Country Link
EP (1) EP1328254B1 (en)
JP (1) JP2004511572A (en)
AT (1) ATE354350T1 (en)
AU (1) AU2002214854A1 (en)
CA (1) CA2426244A1 (en)
DE (1) DE60126801T2 (en)
WO (1) WO2002034236A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002453A1 (en) 2002-06-28 2004-01-08 Protiva Biotherapeutics Ltd. Method and apparatus for producing liposomes
EP1648519B1 (en) * 2003-07-16 2014-10-08 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
JP5166022B2 (en) 2004-05-05 2013-03-21 サイレンス・セラピューティクス・アーゲー Lipids, lipid complexes, and uses thereof
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
EP1781593B1 (en) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Cationic lipids and methods of use
CA2572439A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
AU2005306533B2 (en) * 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
AU2005316213C1 (en) * 2004-12-16 2011-08-25 Protech Research Pty Ltd Transfer of molecules
WO2006063411A2 (en) * 2004-12-16 2006-06-22 Protech Research Pty Ltd Transfer of molecules
KR101366482B1 (en) 2004-12-27 2014-02-21 사일런스 테라퓨틱스 아게 Coated lipid complexes and their use
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
CA2658550C (en) 2006-07-21 2018-06-19 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
EP2125031B1 (en) 2006-12-19 2017-11-01 Marina Biotech, Inc. Lipids and lipid assemblies comprising transfection enhancer elements
JP5501224B2 (en) * 2007-05-25 2014-05-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Formulations and related methods for oral administration of therapeutic agents
JP2011506432A (en) * 2007-12-10 2011-03-03 エピターゲット・アーエス Acoustically sensitive drug delivery particles containing non-lamellar-forming lipids
CN102119217B (en) 2008-04-15 2015-06-03 普洛体维生物治疗公司 Novel lipid formulations for nucleic acid delivery
ES2475065T3 (en) 2008-10-09 2014-07-10 Tekmira Pharmaceuticals Corporation Enhanced amino acids and methods for nucleic acid administration
AU2009320006A1 (en) 2008-10-30 2010-06-03 Peixuan Guo Membrane-integrated viral DNA-packaging motor protein connector biosensor for DNA sequencing and other uses
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
CA2767129C (en) 2009-07-01 2015-01-06 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein b
IL292615B2 (en) 2009-07-01 2023-11-01 Protiva Biotherapeutics Inc Nucleic acid-lipid particles, compositions comprising the same and uses thereof
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
NZ600616A (en) 2009-12-01 2014-11-28 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
KR102128248B1 (en) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
SG11201506116XA (en) 2013-02-05 2015-09-29 1Globe Health Inst Llc Biodegradable and clinically-compatible nanop articles as drug delivery carriers
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
DK2968586T3 (en) 2013-03-14 2018-10-08 Translate Bio Inc CFTR MRNA COMPOSITIONS AND RELATED PROCEDURES AND APPLICATIONS
JP2016175841A (en) * 2013-08-02 2016-10-06 三郎 斎藤 Liposome, and vaccine composition that induces cytotoxic t lymphocyte activity
MX2016005239A (en) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Mrna therapy for phenylketonuria.
WO2015061500A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for argininosuccinate synthetase deficiency
KR102507624B1 (en) 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 C/ebp alpha short activating rna compositions and methods of use
JP6571679B2 (en) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド Method for purifying messenger RNA
CN108096189A (en) * 2016-11-25 2018-06-01 国家纳米科学中心 A kind of elaioplast nanometer particle and its pharmaceutical composition and application
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
MA49138A (en) 2017-05-16 2020-03-25 Translate Bio Inc TREATMENT OF CYSTIC FIBROSIS BY ADMINISTRATION OF CODON-OPTIMIZED MRNA CODING FOR CFTR
EP4219715A3 (en) 2017-09-08 2023-09-06 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP3775211B1 (en) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
AU2019325702A1 (en) 2018-08-24 2021-02-25 Translate Bio, Inc. Methods for purification of messenger RNA
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
CN110638759A (en) * 2019-10-29 2020-01-03 珠海丽凡达生物技术有限公司 A preparation for in vitro transfection and in vivo mRNA delivery
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
KR20230160872A (en) 2021-03-26 2023-11-24 미나 테라퓨틱스 리미티드 TMEM173 SARNA composition and methods of use
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6287591B1 (en) * 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
AU8525098A (en) * 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
EP1173600A2 (en) * 1999-04-20 2002-01-23 The University Of British Columbia Cationic peg-lipids and methods of use

Also Published As

Publication number Publication date
CA2426244A1 (en) 2002-05-02
JP2004511572A (en) 2004-04-15
EP1328254B1 (en) 2007-02-21
DE60126801T2 (en) 2007-12-06
WO2002034236A3 (en) 2003-01-09
ATE354350T1 (en) 2007-03-15
WO2002034236A2 (en) 2002-05-02
EP1328254A2 (en) 2003-07-23
DE60126801D1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
AU2002214854A1 (en) Lipid formulations for target delivery
WO2006012502A3 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2002058622A3 (en) Sn-38 lipid complexes and methods of use
EP1149115A4 (en) METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41
WO2000062813A3 (en) Cationic peg-lipids and methods of use
CA2259179A1 (en) Emulsion formulations for hydrophilic active agents
WO2004090108A3 (en) Irna conjugates
AU2001263106A1 (en) Navigation system, method and software for foot travel
WO2001082932A3 (en) Methods and compositions for enhancing cellular function through protection of tissue components
WO2003077861A3 (en) Water-based delivery systems
WO2004091578A3 (en) Novel encochleation methods, cochleates and methods of use
WO2006013369A3 (en) Compositions forming non-lamellar dispersions
WO2003000233A3 (en) Delivery of small hydrophilic molecules packaged into lipid vesicles
PL1643833T3 (en) Agrochemical formulations
BR0105457A (en) Therapeutic combinations to stimulate bone growth
WO2009141450A3 (en) Liposomes for drug delivery and methods for preparation thereof
WO2007117550A3 (en) Methods for coacervation induced liposomal encapsulation and formulations thereof
WO2004067063A3 (en) Improved formulations for transmucosal vaginal delivery of bisphosphonates
WO2002015959A3 (en) Compounds and compositions for delivering active agents
CA2483916A1 (en) Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
BR0112258A (en) Poorly Water Soluble Drug Delivery System
WO2003035032A3 (en) New non-phospholipid lipid vesicles (nplv) and their use in cosmetic, therapeutic and prophylactic applications
WO2008008827A3 (en) Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures
WO2002038106A3 (en) Calcilytic compounds